PALISADE BIO, INC. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PALISADE BIO, INC. stock issued during period, shares, new issues for the quarter ending 2015-12-31 was -749.93K shares.
- PALISADE BIO, INC. stock issued during period, shares, new issues for the quarter ending 2015-09-30 was 0.00 shares.
- PALISADE BIO, INC. stock issued during period, shares, new issues for the quarter ending 2013-06-30 was 0.00 shares.
- PALISADE BIO, INC. stock issued during period, shares, new issues for the quarter ending 2013-03-31 was 350.65K shares.
- PALISADE BIO, INC. stock issued during period, shares, new issues for fiscal 2015 was 62.49K shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2015-12-31 | -749.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-23 | 62.49K shares 10-K · filed 2017-03-23 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | |
| 2013-03-31 | 350.65K shares 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |